Search Results - vaccine

16 Results

Sort By:

Method to Enhance Pulmonary Dendritic Cell-mediated DNA Vaccination

Unmet NeedWith lung diseases, namely influenza and lung cancer, on the rise, pulmonary vaccination is a promising approach to elicit strong immunity to inhaled pathogens and lung cancer compared to systemic immunization strategies. In particular, inhaled DNA vaccination, a rapidly developing field, can potentially promote humoral and cellular immunity...

Published: 5/9/2024 | Inventor(s): Jung Soo Suk, Yoo Chun Kim, Justin Hanes

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Immunotherapy, Infectious Diseases, Influenza, Lung Cancer, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Tuberculosis (TB), Vaccine

Category(s): Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB), Clinical and Disease Specializations > Infectious Diseases > Influenza, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

Multi-epitope Fusion Antigen Vaccine for ETEC

Unmet Need: Enterotoxigenic Escherichia coli (ETEC) is the leading cause of diarrheal diseases worldwide but to date no effective vaccine exists due to the heterogeneity in ETEC strains. There is a need for a vaccine that elicits a broad yet productive immune response against multiple ETEC antigens to provide protection. Technical Details: Researchers...

Published: 5/9/2024 | Inventor(s): Weiping Zhang, David Sack

Keywords(s): Biologics, Disease Indication, Drug Delivery Mechanism, Immunotherapy, Infectious Diseases, Oral Administration, Protein, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Compositions and Methods for Treating Melanoma--Further Modifications

Unmet NeedTherapeutic cancer vaccines aim to activate the antitumor T cell response. These vaccines are designed to prime naïve antitumor T cells, by activating antigen presenting cells, particularly dendritic cells (DCs). DNA-based cancer vaccines are a particularly promising approach, partially due to the ease with which they can be manufactured....

Published: 5/9/2024 | Inventor(s): Richard Markham, James Gordy

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Melanoma, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines

Hepatitis C virus E1E2 genes stimulating development of broadly neutralizing antibodies

Unmet Need185 million people worldwide are infected with Hepatitis C (HCV). It is a major cause of liver failure and hepatocellular carcinoma. Recent development of potent, oral, interferon-free therapies have improved treatment of HCV significantly, but treatment alone is unlikely to eradicate the disease. There remain the issues of therapy being costly,...

Published: 5/9/2024 | Inventor(s): Justin Bailey, James Crowe, Andrew Flyak, George Shaw, Stuart Ray

Keywords(s): Biologics, Disease Indication, Hepatitis C Virus, Hepatitis C Virus (HCV), Infectious Diseases, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine, Viral Infections

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Hepatitis C Virus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections

Antibody-based Vectored Immunoprophylaxis Provides High-titer Plasmodium Falciparum Circumsporozoites Antibodies

Antibody-based immunoprophylaxis antimalarial therapyJHU REF: [C12545]Invention novelty: an improved antibody-based malarial therapyValue PropositionMalaria remains one of the world’s major causes of death, especially in Africa. Ninety percent of malaria mortalities occur in Africa, where it accounts for about one in five childhood deaths. WHO reported...

Published: 5/9/2024 | Inventor(s): Gary Ketner

Keywords(s): Antibodies, Biologics, Disease Indication, Infectious Diseases, Malaria, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Malaria

Autoimmunity-based Peptides as Cancer Vaccines

Autoimmunity-based Peptides as Cancer Vaccines JHU REF: C12807 Invention novelty: This technology uses autoantigen-derived peptides as novel immunotherapy to prevent and treat cancer. Value Proposition: Today, millions of people are living with cancer or have had cancer. Despite significant advances in cancer diagnosis and treatment over the...

Published: 5/9/2024 | Inventor(s): Erika Darrah, Christine Joseph, Kenneth Kinzler, Livia Casciola-Rosen, Nickolas Papadopoulos, Ami Shah, Antony Rosen, Bert Vogelstein

Keywords(s): Antigens, Biologics, Cancers, Disease Indication, Immunotherapy, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Vaccines

PD-1/PD-L1 Blockade together with Vaccine Therapy Facilitates Effector T Cell Infiltration into Pancreatic Tumors

Novel Combination Therapy for Pancreatic Cancer TreatmentJHU REF: C12915Invention Novelty: The technology is the novel combination of PD1/PD-L1 blockade antibody and vaccine-based immunotherapy to treat pancreatic cancer.Value Proposition:Pancreatic cancer is one of the top cancer killers in the United States due to late detection and resistance to...

Published: 5/9/2024 | Inventor(s): Elizabeth Jaffee, Lei Zheng

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Pancreatic Cancer, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

MART-1 Phosphopeptides Restricted by HLA-DR1 for use as Melanoma Vaccines

C10691: Novel Peptides as a Melanoma Vaccine Value Proposition: • Phosphopeptides for use as vaccines for therapy and prevention of melanoma • Phosphopeptides for robust, diverse, and long-lasting anti-tumor immunity • Specific activity against whole melanoma tumor cells in vitro • Stand alone therapy/Combination Therapy •...

Published: 5/9/2024 | Inventor(s): Donald Hunt, Florence Depontieu, Angela Zarling, Victor Engelhard, Jeffrey Shabanowitz, Jie Qian, Suzanne Topalian

Keywords(s): Biologics, Cancers, Disease Indication, Immunotherapy, Melanoma, Peptide, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

A Malaria Vaccine Based on CH-rPfs 48/45 Antigen and Adjuvant Formulations to Stop Malaria Transmission

C10497: A Malaria Vaccine to Stop Malaria Transmission Technical Details: Malaria is a disease caused by parasites of the genus Plasmodium. It affects near 2 billion people worldwide and results in 1-2 million deaths every year. Transmission-blocking vaccines (TBV) have received attention as potentially effective strategy in the fight against malaria....

Published: 5/9/2024 | Inventor(s): Evelina Angov, Nirbhay Kumar

Keywords(s): Adjuvant, Biologics, Disease Indication, Infectious Diseases, Malaria, Parasitic Infections, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Infectious Diseases

C04942: Vaccine against E. Coli Bacteremia and sepsis

Value Proposition: E. coli is the most common gram-negative organism causing nosocomial bacteremia related infection in elderly patients. The mortality and morbidity associated with E. coli bacteremia is substantial. E. coli sepsis is associated with an estimated 40,000 deaths each year at a cost of two billion dollars in the US alone. JHU inventors...

Published: 5/9/2024 | Inventor(s): Kwang Kim

Keywords(s): Bacteria, Bacterial Infections, Biologics, Disease Indication, E. Coli, Escherichia coli, Food Borne Diseases, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections, Clinical and Disease Specializations > Infectious Diseases > Escherichia coli, Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

1 2